SEC Comment Letter 0000000000-25-003347 to Semnur Pharmaceuticals, Inc. (SMNR)
Semnur Pharmaceuticals, Inc.
Date: March 28, 2025 · CIK: 0001913577 · Accession: 0000000000-25-003347
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 001-41351
Letter
Re: Denali Capital Acquisition Corp. Preliminary Proxy Statement on Schedule 14A Filed March 20, 2025 File No. 001-41351 Dear Lei Huang:
March 28, 2025
Lei Huang Chief Executive Officer Denali Capital Acquisition Corp. 437 Madison Avenue, 27th Floor New York, NY 10022
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation
Finance
Office of Life Sciences
cc: Michael Blankenship, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> March 28, 2025 Lei Huang Chief Executive Officer Denali Capital Acquisition Corp. 437 Madison Avenue, 27th Floor New York, NY 10022 Re: Denali Capital Acquisition Corp. Preliminary Proxy Statement on Schedule 14A Filed March 20, 2025 File No. 001-41351 Dear Lei Huang: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Michael Blankenship, Esq. </TEXT> </DOCUMENT>